Published in Arthritis Rheum on February 09, 1976
Reaction of systemic lupus erythematosus antinative DNA antibodies with native DNA fragments from 20 to 1,200 base pairs. J Clin Invest (1980) 1.57
Secondary structure in denatured DNA is responsible for its reaction with antinative DNA antibodies of systemic lupus erythematosus sera. J Clin Invest (1980) 1.32
Correlation between levels of DNA antibodies and clinical disease activity in SLE. Ann Rheum Dis (1977) 1.32
The significance of antibodies to poly(adenosine diphosphate-ribose) in systemic lupus erythematosus. Clin Exp Immunol (1979) 1.21
Detection of anti-dsDNA as diagnostic tool. Ann Rheum Dis (1981) 1.21
Evaluation of fluorescent antinuclear antibody assays, Crithidia luciliae substrate, and single-stranded DNA-binding capacity in diagnosis of four rheumatic diseases. J Clin Microbiol (1982) 1.07
Molecular analysis of complement-fixing rheumatoid synovial fluid immune complexes. Clin Exp Immunol (1981) 1.05
Autoantibody profile in juvenile chronic arthritis. Ann Rheum Dis (1988) 1.02
Juvenile chronic arthritis, chronic iridocyclitis, and reactivity to histones. Ann Rheum Dis (1991) 0.78
Antibody to synthetic poly dAT: correlation with antibody to native DNA and specificity for SLE. J Clin Pathol (1980) 0.75
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 67.54
Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis (2002) 20.48
Immunological studies concerning the nephritis of systemic lupus erythematosus. J Exp Med (1967) 10.22
Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest (1966) 8.64
Measurement of serum DNA-binding activity in systemic lupus erythematosus. N Engl J Med (1969) 6.16
Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med (1968) 5.95
Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J Exp Med (1978) 4.28
Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum (1989) 4.02
Differentiation and characterization of autoantibodies and their antigens in Sjögren's syndrome. Arthritis Rheum (1976) 4.02
The pathogenesis of autoimmunity in New Zealand black mice. Curr Top Microbiol Immunol (1974) 3.98
Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N Engl J Med (1980) 3.95
The histopathology of Sjögren's syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol (1974) 3.82
Assignment of direct and facilitated hemolytic plaques in mice to specific immunoglobulin classes. J Immunol (1968) 3.81
Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus. N Engl J Med (1982) 3.40
Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Am J Pathol (1985) 3.31
The pathogenesis of arthritis associated with viral hepatitis. Complement-component studies. N Engl J Med (1971) 3.31
Does this patient have an abnormal systolic murmur? JAMA (1997) 3.00
Extrasalivary lymphoid abnormalities in Sjögren's syndrome (reticulum cell sarcoma, "pseudolymphoma," macroglobulinemia). Am J Med (1967) 2.92
Xerostomia in Sjögren's syndrome. Evaluation by sequential salivary scintigraphy. JAMA (1971) 2.89
Effectiveness of source documents for identifying fatal occupational injuries: a synthesis of studies. Am J Public Health (1991) 2.84
Relative inability to induce tolerance in adult NZB and NZB-NZW F1 mice. J Exp Med (1969) 2.78
Impaired Lymphocyte Transformation and Delayed Hypersensitivity in Sjögren's Syndrome. J Clin Invest (1967) 2.77
Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum (1988) 2.77
Immunologic and viral factors in the pathogenesis of systemic lupus erythematosus. Arthritis Rheum (1971) 2.66
Activation of the properdin pathway of complement in patients with gram-negative of bacteremia. N Engl J Med (1975) 2.63
Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med (1992) 2.63
Disordered immunologic regulation and autoimmunity. Transplant Rev (1976) 2.62
Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene. J Exp Med (1981) 2.46
Transmission from vasoconstrictor and vasodilator nerves to single smooth muscle cells of the guinea-pig uterine artery. J Physiol (1969) 2.42
Fractionation of splenic antibody-forming cells on glass bead columns. J Immunol (1967) 2.41
Inherited deficiency of the second component of complement. Rheumatic disease associations. J Clin Invest (1976) 2.38
B cells expressing CD5 are increased in Sjögren's syndrome. Arthritis Rheum (1988) 2.37
A computer based intervention to reduce unnecessary serologic testing. J Rheumatol (1999) 2.37
Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis (2003) 2.33
Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33
Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. J Clin Invest (1977) 2.33
The pathogenesis of autoimmunity in New Zealand mice, I. Induction of antinucleic acid antibodies by polyinosinic-polycytidylic acid. Proc Natl Acad Sci U S A (1969) 2.31
Genomewide search for type 2 diabetes susceptibility genes in four American populations. Am J Hum Genet (2000) 2.19
Synergy among lymphoid cells mediating the graft-versus-host response. I. Synergy in graft-versus-host reactions produced by cells from NZB-Bl mice. J Exp Med (1970) 2.15
Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet (2000) 2.13
DNA-binding assay for detection of anti-DNA antibodies in NZB-NZW F1 mice. J Immunol (1969) 2.13
Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest (1996) 2.07
Alterations in immunoregulatory T cell subsets in active systemic lupus erythematosus. J Clin Invest (1980) 2.06
beta-Estradiol reduces natural killer cells in mice. J Immunol (1978) 2.02
The spectrum of benign to malignant lymphoproliferation in Sjögren's syndrome. Clin Exp Immunol (1972) 2.01
Silicone breast implants and rheumatic disease. Clinical, immunologic, and epidemiologic studies. Arthritis Rheum (1994) 1.97
Screening for non-gonococcal urethritis. Int J STD AIDS (2003) 1.92
Filter radioimmunoassay for antibodies to reovirus RNA in systemic lupus erythematosus. Arthritis Rheum (1974) 1.92
Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunol (1981) 1.89
Establishment and characterization of a murine hybridoma secreting monoclonal anti-DNA autoantibody. J Immunol (1980) 1.88
Modulation of host response to Escherichia coli o157:H7 infection by anti-CD18 antibody in rabbits. Gastroenterology (1994) 1.85
Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore) (1981) 1.83
Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol (1984) 1.81
Immunological regulation of spontaneous antibodies to DNA and RNA. II. Sequential switch from IgM to IgG in NZB/NZW F1 mice. Immunology (1977) 1.80
Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry (1995) 1.80
Selective gamma-g globulin deficiencies in patients with recurrent pyogenic infections. N Engl J Med (1970) 1.80
Antibodies to ribonucleic acid in systemic lupus erythematosus. Proc Natl Acad Sci U S A (1969) 1.79
The neuropathy of Sjögren's syndrome. Trigeminal nerve involvement. Ann Intern Med (1969) 1.79
Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun (1986) 1.79
Complement in human disease. Annu Rev Med (1968) 1.79
Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol (1995) 1.75
The clearance and localization of nucleic acids by New Zealand and normal mice. Clin Exp Immunol (1972) 1.74
Cost-utility analyses of clinical preventive services: published ratios, 1976-1997. Am J Prev Med (2000) 1.72
Renal tubular acidosis, glomerulonephritis and immunologic factors in Sjögren's syndrome. Arthritis Rheum (1968) 1.72
The oral component of Sjögren's syndrome. Oral Surg Oral Med Oral Pathol (1975) 1.70
Cyclophosphamide in lupus nephritis: a controlled trial. Ann Intern Med (1971) 1.70
Serum complement component levels in human glomerulonephritis. Ann Intern Med (1971) 1.70
A method for increasing the sensitivity of radial-immunodiffusion assay. Lancet (1970) 1.70
Lymphocyte surface immunoglobulins. Distribution and frequency in lymphoproliferative diseases. N Engl J Med (1973) 1.69
The pathogenesis of autoimmunity in New Zealand mice. 3. Factors influencing the formation of anti-nucleic acid antibodies. Immunology (1971) 1.68
Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. J Exp Med (1997) 1.66
Immunologic studies of juvenile rheumatoid arthritis. Arthritis Rheum (1972) 1.65
Advances in the diagnosis and concept of Sjögren's syndrome (autoimmune exocrinopathy). Bull Rheum Dis (1980) 1.64
T and B lymphocytes in peripheral blood and tissue lesions in Sjögren's syndrome. J Clin Invest (1974) 1.63
Heavy chain subclass of human anti-platelet antibodies. Clin Immunol Immunopathol (1973) 1.61
Interleukin-2 in rheumatoid arthritis: production of and response to interleukin-2 in rheumatoid synovial fluid, synovial tissue and peripheral blood. Clin Exp Immunol (1985) 1.61
The usefulness of a tracking catheter in complex coronary angioplasty. Cathet Cardiovasc Diagn (1992) 1.60
Induction of immunologic tolerance in older New Zealand mice repopulated with young spleen, bone marrow, or thymus. J Exp Med (1970) 1.58
Genome scan for human obesity and linkage to markers in 20q13. Am J Hum Genet (1999) 1.58
SLE-like autoantibodies and Sjögren's syndrome-like lymphoproliferation in TGF-beta knockout mice. J Immunol (1995) 1.57
Enzyme immunoassay for antibodies to native DNA. Specificity and quality of antibodies. Arthritis Rheum (1983) 1.56
A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies. Med Decis Making (2001) 1.55
Dual vasoconstrictor and vasodilator innervation of the uterine arterial supply in the guinea pig. Circ Res (1968) 1.54
Presumed tuberculous uveitis: diagnosis, management, and outcome. Eye (Lond) (2011) 1.54
Evidence that the malignant lymphoma of Sjögren's syndrome is a monoclonal B-cell neoplasm. N Engl J Med (1978) 1.54
Response of NZB and NZB-NZW spleen cells to mitogenic agents. J Immunol (1970) 1.54
Decreased autologous mixed lymphocyte reaction in Sjögren's syndrome. J Clin Invest (1980) 1.52
Serum and synovial fluid IgG, IgA and IgM antigammaglobulins in rheumatoid arthritis. Arthritis Rheum (1972) 1.51
Clinical laboratory test findings in patients with chronic fatigue syndrome. Arch Intern Med (1995) 1.50
Detection of Berry's phase in a Bulk Rashba semiconductor. Science (2013) 1.49
Shared idiotypes and restricted immunoglobulin variable region heavy chain genes characterize murine autoantibodies of various specificities. J Clin Invest (1986) 1.48
Hypocomplementemia in rheumatoid arthritis. Arthritis Rheum (1971) 1.48
Two-dimensional normal-state quantum oscillations in a superconducting heterostructure. Nature (2009) 1.47
Complement components in synovial fluid: activation and fixation in seropositive rheumatoid arthritis. Ann N Y Acad Sci (1969) 1.46
IgG subclasses--a review. Ann Allergy (1987) 1.45
Immunoglobulin synthesis by salivary gland lymphoid cells in Sjögren's syndrome. J Clin Invest (1970) 1.44
Sjögren's syndrome comes of age. Semin Arthritis Rheum (1999) 1.43
Delayed androgen treatment prolongs survival in murine lupus. J Clin Invest (1979) 1.43